FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296947286> ?p ?o ?g. }

• W2296947286 endingPage "19747" @default.
• W2296947286 startingPage "19738" @default.
• W2296947286 abstract "// Francesco Passiglia 1, * , Giuseppe Bronte 1, * , Viviana Bazan 1, * , Clara Natoli 2 , Sergio Rizzo 1 , Antonio Galvano 1 , Angela Listì 1 , Giuseppe Cicero 1 , Christian Rolfo 3 , Daniele Santini 4 , Antonio Russo 1 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy 3 Phase I- Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium 4 Medical Oncology Department, Campus Biomedico, University of Rome, Rome, Italy * These authors have contributed equally to this work Correspondence to: Antonio Russo, e-mail: antonio.russo@usa.net Keywords: PD-L1, predictive biomarker, immunotherapy, anti-PD1/PD-L1 MoAbs, NSCLC Received: December 03, 2015     Accepted: February 11, 2016     Published: February 22, 2016 ABSTRACT Background: Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 expression is still controversial. This pooled analysis aims to clarify the association of clinical objective responses to anti PD-1/PD-L1 monoclonal antibodies (MoAbs) and tumor PD-L1 expression in pre-treated NSCLC patients. Methods: Data from published studies, that evaluated efficacy and safety of PD-1/PD-L1 inhibitors in pre-treated NSCLC patients, stratified by tumor PD-L1 expression status (immunohistochemistry, cut-off point 1%), were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, European Society of Medical Oncology and World Conference of Lung Cancer, meeting proceedings. Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for the Overall Response Rate (ORR) (as evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1), according to PD-L1 expression status. Results: A total of seven studies, with 914 patients, were eligible. Pooled analysis showed that patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68). Conclusions: PD-L1 tumor over-expression seems to be associated with higher clinical activity of anti PD-1/PD-L1 MoAbs, in pre-treated NSCLC patients, suggesting a potential role of PD-L1 expression, IHC cut-off point 1%, as predictive biomarker for the selection of patients to treat with immune-checkpoint inhibitors." @default.
• W2296947286 created "2016-06-24" @default.
• W2296947286 creator A5000995161 @default.
• W2296947286 creator A5004175335 @default.
• W2296947286 creator A5006712720 @default.
• W2296947286 creator A5027075905 @default.
• W2296947286 creator A5033609878 @default.
• W2296947286 creator A5055919267 @default.
• W2296947286 creator A5072264918 @default.
• W2296947286 creator A5074506844 @default.
• W2296947286 creator A5084174977 @default.
• W2296947286 creator A5091765229 @default.
• W2296947286 date "2016-02-22" @default.
• W2296947286 modified "2023-10-01" @default.
• W2296947286 title "PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis" @default.
• W2296947286 cites W1498931318 @default.
• W2296947286 cites W1548051998 @default.
• W2296947286 cites W1829889233 @default.
• W2296947286 cites W1889335134 @default.
• W2296947286 cites W1965071545 @default.
• W2296947286 cites W1982488143 @default.
• W2296947286 cites W1984545852 @default.
• W2296947286 cites W1997134098 @default.
• W2296947286 cites W2005253379 @default.
• W2296947286 cites W2007872832 @default.
• W2296947286 cites W2038914273 @default.
• W2296947286 cites W2039123767 @default.
• W2296947286 cites W2049553585 @default.
• W2296947286 cites W2056451421 @default.
• W2296947286 cites W2066671159 @default.
• W2296947286 cites W2075027825 @default.
• W2296947286 cites W2098005365 @default.
• W2296947286 cites W2099560139 @default.
• W2296947286 cites W2100158834 @default.
• W2296947286 cites W2102786125 @default.
• W2296947286 cites W2104347254 @default.
• W2296947286 cites W2106511606 @default.
• W2296947286 cites W2109485845 @default.
• W2296947286 cites W2115536507 @default.
• W2296947286 cites W2118471749 @default.
• W2296947286 cites W2122639773 @default.
• W2296947286 cites W2124427232 @default.
• W2296947286 cites W2131950300 @default.
• W2296947286 cites W2136731993 @default.
• W2296947286 cites W2138619415 @default.
• W2296947286 cites W2143488876 @default.
• W2296947286 cites W2147415023 @default.
• W2296947286 cites W2156353875 @default.
• W2296947286 cites W2160834915 @default.
• W2296947286 cites W2220506303 @default.
• W2296947286 cites W2329185469 @default.
• W2296947286 cites W2560367415 @default.
• W2296947286 cites W2572174216 @default.
• W2296947286 cites W2015461352 @default.
• W2296947286 doi "https://doi.org/10.18632/oncotarget.7582" @default.
• W2296947286 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4991415" @default.
• W2296947286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26918451" @default.
• W2296947286 hasPublicationYear "2016" @default.
• W2296947286 type Work @default.
• W2296947286 sameAs 2296947286 @default.
• W2296947286 citedByCount "125" @default.
• W2296947286 countsByYear W22969472862016 @default.
• W2296947286 countsByYear W22969472862017 @default.
• W2296947286 countsByYear W22969472862018 @default.
• W2296947286 countsByYear W22969472862019 @default.
• W2296947286 countsByYear W22969472862020 @default.
• W2296947286 countsByYear W22969472862021 @default.
• W2296947286 countsByYear W22969472862022 @default.
• W2296947286 countsByYear W22969472862023 @default.
• W2296947286 crossrefType "journal-article" @default.
• W2296947286 hasAuthorship W2296947286A5000995161 @default.
• W2296947286 hasAuthorship W2296947286A5004175335 @default.
• W2296947286 hasAuthorship W2296947286A5006712720 @default.
• W2296947286 hasAuthorship W2296947286A5027075905 @default.
• W2296947286 hasAuthorship W2296947286A5033609878 @default.
• W2296947286 hasAuthorship W2296947286A5055919267 @default.
• W2296947286 hasAuthorship W2296947286A5072264918 @default.
• W2296947286 hasAuthorship W2296947286A5074506844 @default.
• W2296947286 hasAuthorship W2296947286A5084174977 @default.
• W2296947286 hasAuthorship W2296947286A5091765229 @default.
• W2296947286 hasBestOaLocation W22969472861 @default.
• W2296947286 hasConcept C121608353 @default.
• W2296947286 hasConcept C126322002 @default.
• W2296947286 hasConcept C143998085 @default.
• W2296947286 hasConcept C185592680 @default.
• W2296947286 hasConcept C2777701055 @default.
• W2296947286 hasConcept C2781197716 @default.
• W2296947286 hasConcept C535046627 @default.
• W2296947286 hasConcept C55493867 @default.
• W2296947286 hasConcept C71924100 @default.
• W2296947286 hasConceptScore W2296947286C121608353 @default.
• W2296947286 hasConceptScore W2296947286C126322002 @default.
• W2296947286 hasConceptScore W2296947286C143998085 @default.
• W2296947286 hasConceptScore W2296947286C185592680 @default.
• W2296947286 hasConceptScore W2296947286C2777701055 @default.
• W2296947286 hasConceptScore W2296947286C2781197716 @default.
• W2296947286 hasConceptScore W2296947286C535046627 @default.
• W2296947286 hasConceptScore W2296947286C55493867 @default.

• next